Weight Loss Drug ETFs: GLP-1 & Obesity Treatment Funds
GLP-1 receptor agonists — the drug class behind brand names like Ozempic, Wegovy, and Zepbound — were originally developed to treat diabetes before researchers discovered their significant effect on appetite suppression and weight loss. Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), currently dominate this market, but a growing number of firms are pursuing alternatives, including Amylin analogs and combination therapies.
A small but dedicated group of ETFs now tracks this theme directly:
- OZEM (Roundhill GLP-1 & Weight Loss ETF): Described as the world’s first GLP-1 ETF, this actively managed fund launched in May 2024 on the Nasdaq. It invests at least 80% of net assets in GLP-1 and weight loss companies, spanning pure-play drug makers, diversified therapeutics firms, and other weight loss enablers.
- THNR (Amplify Weight Loss Drug & Treatment ETF): A passively managed fund tracking the VettaFi Weight Loss Drug & Treatment Index, listed on NYSE Arca. The index allocates roughly 70% to drug manufacturers and 30% to enablers such as outsourced development and distribution companies. It holds approximately 22 securities and rebalances quarterly.
- HRTS (Tema Heart & Health ETF): Actively managed by Dr. David Song, this fund takes a broader cardiometabolic approach, covering GLP-1 treatments alongside cardiovascular and metabolic disease therapies. Its scientific advisory board includes GLP-1 pioneer Professor Jens Juul Holst. The fund typically holds around 45 positions across U.S. and European markets.
Beyond weight management, early research suggests GLP-1 drugs may have applications in cardiovascular risk reduction, Parkinson’s symptom management, and even Alzheimer’s and addiction — areas that could widen the addressable market for companies in these ETFs. For a broader look at the sector, see our list of the largest pharmaceutical companies by market cap or explore largest healthcare companies.
Regulated brokerThe table below shows weight loss drug and treatment ETFs with live pricing, performance, and fund details.
| Stock | Price | Change % | 52 Week Range |
|---|---|---|---|
| $32.77 | 1.35% | ||
| $83.99 | 1.27% | ||
| $100.73 | 1.25% | ||
| $31.85 | 1.23% | ||
| $98.71 | 3.28% | ||
| $60.62 | 0.92% | ||
| $145.38 | 0.84% | ||
| $91.33 | 1.39% | ||
| $69.25 | 0.99% | ||
| $269.11 | 1.03% | ||
| $100.19 | 1.30% |
